TNF: A moonlighting protein at the interface between cancer and infection

Harald Hundsberger, Alexander Dmitriyevich Verin, Christoph Wiesner, Maren Pflüger, Alexander Dulebo, Wolfgang Schütt, Ignace Lasters, Daniela N. Männel, Albrecht Wendel, Rudolf Lucas

Research output: Contribution to journalReview article

33 Citations (Scopus)

Abstract

The remarkable ability of TNF, especially in combination with Interferon-gamma or melphalan, to inhibit the growth of malignant tumor cells is so far unmatched. Unfortunately, its high systemic toxicity and hepatotoxicity prevent its systemic use in cancer patients. An elegant manner to circumvent this problem is the isolated limb and liver perfusion for the treatment of melanoma, soft tissue sarcoma and liver tumors, respectively, although the latter method can lead to a reversible hepatotoxicity. In order to allow also the treatment of other cancers with TNF, new strategies have to be developed that aim at sensitizing tumor cells to TNF and at reducing its systemic and liver toxicity, without losing its antitumor efficiency. Moreover, the lectin-like domain of TNF, which is spatially distinct from the receptor binding sites, could be useful in reducing cancer treatment-related pulmonary edema formation. This review will discuss some recent developments in these areas, which can lead to a renewed interest in TNF for the systemic treatment of cancer.

Original languageEnglish (US)
Pages (from-to)5374-5386
Number of pages13
JournalFrontiers in Bioscience
Volume13
Issue number14
DOIs
StatePublished - May 1 2008

Fingerprint

Liver
Tumors
Toxicity
Infection
Cells
Neoplasms
Proteins
Melphalan
Oncology
Lectins
Interferon-gamma
Binding Sites
Tissue
Second Primary Neoplasms
Pulmonary Edema
Sarcoma
Melanoma
Therapeutics
Extremities
Perfusion

Keywords

  • ATP
  • Edema
  • Hepatotoxicity
  • Lectin-like domain
  • Review
  • TNF receptor 2
  • Tumor necrosis factor

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Immunology and Microbiology(all)

Cite this

TNF : A moonlighting protein at the interface between cancer and infection. / Hundsberger, Harald; Verin, Alexander Dmitriyevich; Wiesner, Christoph; Pflüger, Maren; Dulebo, Alexander; Schütt, Wolfgang; Lasters, Ignace; Männel, Daniela N.; Wendel, Albrecht; Lucas, Rudolf.

In: Frontiers in Bioscience, Vol. 13, No. 14, 01.05.2008, p. 5374-5386.

Research output: Contribution to journalReview article

Hundsberger, H, Verin, AD, Wiesner, C, Pflüger, M, Dulebo, A, Schütt, W, Lasters, I, Männel, DN, Wendel, A & Lucas, R 2008, 'TNF: A moonlighting protein at the interface between cancer and infection', Frontiers in Bioscience, vol. 13, no. 14, pp. 5374-5386. https://doi.org/10.2741/3087
Hundsberger H, Verin AD, Wiesner C, Pflüger M, Dulebo A, Schütt W et al. TNF: A moonlighting protein at the interface between cancer and infection. Frontiers in Bioscience. 2008 May 1;13(14):5374-5386. https://doi.org/10.2741/3087
Hundsberger, Harald ; Verin, Alexander Dmitriyevich ; Wiesner, Christoph ; Pflüger, Maren ; Dulebo, Alexander ; Schütt, Wolfgang ; Lasters, Ignace ; Männel, Daniela N. ; Wendel, Albrecht ; Lucas, Rudolf. / TNF : A moonlighting protein at the interface between cancer and infection. In: Frontiers in Bioscience. 2008 ; Vol. 13, No. 14. pp. 5374-5386.
@article{f8072a7b743c475d976a3c92745fc5b3,
title = "TNF: A moonlighting protein at the interface between cancer and infection",
abstract = "The remarkable ability of TNF, especially in combination with Interferon-gamma or melphalan, to inhibit the growth of malignant tumor cells is so far unmatched. Unfortunately, its high systemic toxicity and hepatotoxicity prevent its systemic use in cancer patients. An elegant manner to circumvent this problem is the isolated limb and liver perfusion for the treatment of melanoma, soft tissue sarcoma and liver tumors, respectively, although the latter method can lead to a reversible hepatotoxicity. In order to allow also the treatment of other cancers with TNF, new strategies have to be developed that aim at sensitizing tumor cells to TNF and at reducing its systemic and liver toxicity, without losing its antitumor efficiency. Moreover, the lectin-like domain of TNF, which is spatially distinct from the receptor binding sites, could be useful in reducing cancer treatment-related pulmonary edema formation. This review will discuss some recent developments in these areas, which can lead to a renewed interest in TNF for the systemic treatment of cancer.",
keywords = "ATP, Edema, Hepatotoxicity, Lectin-like domain, Review, TNF receptor 2, Tumor necrosis factor",
author = "Harald Hundsberger and Verin, {Alexander Dmitriyevich} and Christoph Wiesner and Maren Pfl{\"u}ger and Alexander Dulebo and Wolfgang Sch{\"u}tt and Ignace Lasters and M{\"a}nnel, {Daniela N.} and Albrecht Wendel and Rudolf Lucas",
year = "2008",
month = "5",
day = "1",
doi = "10.2741/3087",
language = "English (US)",
volume = "13",
pages = "5374--5386",
journal = "Frontiers in Bioscience - Landmark",
issn = "1093-9946",
publisher = "Frontiers in Bioscience",
number = "14",

}

TY - JOUR

T1 - TNF

T2 - A moonlighting protein at the interface between cancer and infection

AU - Hundsberger, Harald

AU - Verin, Alexander Dmitriyevich

AU - Wiesner, Christoph

AU - Pflüger, Maren

AU - Dulebo, Alexander

AU - Schütt, Wolfgang

AU - Lasters, Ignace

AU - Männel, Daniela N.

AU - Wendel, Albrecht

AU - Lucas, Rudolf

PY - 2008/5/1

Y1 - 2008/5/1

N2 - The remarkable ability of TNF, especially in combination with Interferon-gamma or melphalan, to inhibit the growth of malignant tumor cells is so far unmatched. Unfortunately, its high systemic toxicity and hepatotoxicity prevent its systemic use in cancer patients. An elegant manner to circumvent this problem is the isolated limb and liver perfusion for the treatment of melanoma, soft tissue sarcoma and liver tumors, respectively, although the latter method can lead to a reversible hepatotoxicity. In order to allow also the treatment of other cancers with TNF, new strategies have to be developed that aim at sensitizing tumor cells to TNF and at reducing its systemic and liver toxicity, without losing its antitumor efficiency. Moreover, the lectin-like domain of TNF, which is spatially distinct from the receptor binding sites, could be useful in reducing cancer treatment-related pulmonary edema formation. This review will discuss some recent developments in these areas, which can lead to a renewed interest in TNF for the systemic treatment of cancer.

AB - The remarkable ability of TNF, especially in combination with Interferon-gamma or melphalan, to inhibit the growth of malignant tumor cells is so far unmatched. Unfortunately, its high systemic toxicity and hepatotoxicity prevent its systemic use in cancer patients. An elegant manner to circumvent this problem is the isolated limb and liver perfusion for the treatment of melanoma, soft tissue sarcoma and liver tumors, respectively, although the latter method can lead to a reversible hepatotoxicity. In order to allow also the treatment of other cancers with TNF, new strategies have to be developed that aim at sensitizing tumor cells to TNF and at reducing its systemic and liver toxicity, without losing its antitumor efficiency. Moreover, the lectin-like domain of TNF, which is spatially distinct from the receptor binding sites, could be useful in reducing cancer treatment-related pulmonary edema formation. This review will discuss some recent developments in these areas, which can lead to a renewed interest in TNF for the systemic treatment of cancer.

KW - ATP

KW - Edema

KW - Hepatotoxicity

KW - Lectin-like domain

KW - Review

KW - TNF receptor 2

KW - Tumor necrosis factor

UR - http://www.scopus.com/inward/record.url?scp=52049084323&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=52049084323&partnerID=8YFLogxK

U2 - 10.2741/3087

DO - 10.2741/3087

M3 - Review article

C2 - 18508593

AN - SCOPUS:52049084323

VL - 13

SP - 5374

EP - 5386

JO - Frontiers in Bioscience - Landmark

JF - Frontiers in Bioscience - Landmark

SN - 1093-9946

IS - 14

ER -